This protocol assesses proinflammatory properties of nucleic acid nanoparticles (NANPs) using a validated preclinical model, peripheral blood mononuclear cells (PBMCs), that is highly predictive of cytokine responses. The experimental procedure details the preparation of pyrogen-free NANPs, isolation of PBMCs from freshly collected human blood, and analysis of characteristic biomarkers (type I and III interferons) produced by PBMCs transfected with NANPs. Although representative NANPs with high and low immunostimulatory potential are used as standards throughout the procedure, this protocol can be adapted to any NANPs or therapeutic nucleic acids, irrespective of whether they are carrier based or carrier free; additional cytokine biomarkers can also be included. We test several commercial platforms and controls broadly accessible to the research community to quantify all biomarkers in either single- or multiplex format. The continuous execution of this protocol takes <48 h; when immediate analysis is not feasible, single-use aliquots of the supernatants can be frozen and stored (−20 °C; 12 months).
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Leontis, N. B., Stombaugh, J. & Westhof, E. The non-Watson-Crick base pairs and their associated isostericity matrices. Nucleic Acids Res. 30, 3497–3531 (2002).
Bindewald, E., Hayes, R., Yingling, Y. G., Kasprzak, W. & Shapiro, B. A. RNAJunction: a database of RNA junctions and kissing loops for three-dimensional structural analysis and nanodesign. Nucleic Acids Res. 36, D392–D397 (2008).
Parlea, L. et al. Ring Catalog: a resource for designing self-assembling RNA nanostructures. Methods 103, 128–137 (2016).
Parlea, L. G., Sweeney, B. A., Hosseini-Asanjan, M., Zirbel, C. L. & Leontis, N. B. The RNA 3D Motif Atlas: computational methods for extraction, organization and evaluation of RNA motifs. Methods 103, 99–119 (2016).
Geary, C., Chworos, A., Verzemnieks, E., Voss, N. R. & Jaeger, L. Composing RNA nanostructures from a syntax of RNA structural modules. Nano Lett. 17, 7095–7101 (2017).
Weng, Y. et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol. Ther. Nucleic Acids 19, 581–601 (2019).
Afonin, K. A. et al. Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat. Protoc. 6, 2022–2034 (2011).
Jasinski, D., Haque, F., Binzel, D. W. & Guo, P. Advancement of the emerging field of RNA nanotechnology. ACS Nano 11, 1142–1164 (2017).
Jaeger, L., Westhof, E. & Leontis, N. B. TectoRNA: modular assembly units for the construction of RNA nano-objects. Nucleic Acids Res. 29, 455–463 (2001).
Jaeger, L. & Leontis, N. B. Tecto-RNA: one-dimensional self-assembly through tertiary interactions. Angew. Chem. Int. Ed. Engl. 39, 2521–2524 (2000).
Ohno, H. et al. Synthetic RNA-protein complex shaped like an equilateral triangle. Nat. Nanotechnol. 6, 116–120 (2011).
Dibrov, S. M., McLean, J., Parsons, J. & Hermann, T. Self-assembling RNA square. Proc. Natl Acad. Sci. USA 108, 6405–6408 (2011).
Boerneke, M. A., Dibrov, S. M. & Hermann, T. Crystal-structure-guided design of self-assembling RNA nanotriangles. Angew. Chem. Int. Ed. Engl. 55, 4097–4100 (2016).
Afonin, K. A. et al. In vitro assembly of cubic RNA-based scaffolds designed in silico. Nat. Nanotechnol. 5, 676–682 (2010).
Chidchob, P. & Sleiman, H. F. Recent advances in DNA nanotechnology. Curr. Opin. Chem. Biol. 46, 63–70 (2018).
Rothemund, P. W. K. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297–302 (2006).
Afonin, K. A. et al. Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano 9, 251–259 (2015).
Afonin, K. A. et al. Multifunctional RNA nanoparticles. Nano Lett. 14, 5662–5671 (2014).
Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389–393 (2012).
Li, H. et al. RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano Today 10, 631–655 (2015).
Shu, D., Shu, Y., Haque, F., Abdelmawla, S. & Guo, P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol. 6, 658–667 (2011).
Khisamutdinov, E. F. et al. Enhancing immunomodulation on innate immunity by shape transition among RNA triangle, square and pentagon nanovehicles. Nucleic Acids Res. 42, 9996–10004 (2014).
Halman, J. R. et al. Functionally-interdependent shape-switching nanoparticles with controllable properties. Nucleic Acids Res. 45, 2210–2220 (2017).
Johnson, M. B. et al. Programmable nucleic acid based polygons with controlled neuroimmunomodulatory properties for predictive QSAR modeling. Small 13, 1701255 (2017).
Hong, E. et al. Structure and composition define immunorecognition of nucleic acid nanoparticles. Nano Lett. 18, 4309–4321 (2018).
Hong, E. et al. Toll-like receptor-mediated recognition of nucleic acid nanoparticles (NANPs) in human primary blood cells. Molecules 24, 1094 (2019).
Bindewald, E. et al. Multistrand structure prediction of nucleic acid assemblies and design of RNA switches. Nano Lett. 16, 1726–1735 (2016).
Dobrovolskaia, M. A. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: challenges, considerations and strategy. J. Control. Release 220, 571–583 (2015).
Panigaj, M. et al. Aptamers as modular components of therapeutic nucleic acid nanotechnology. ACS Nano 13, 12301–12321 (2019).
Chandler, M. & Afonin, K. A. Smart-responsive nucleic acid nanoparticles (NANPs) with the potential to modulate immune behavior. Nanomaterials (Basel) 9, 611 (2019).
Sajja, S. et al. Dynamic behavior of RNA nanoparticles analyzed by AFM on a mica/air interface. Langmuir 34, 15099–15108 (2018).
Ke, W. et al. RNA-DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF-kB in human cells. Nucleic Acids Res. 47, 1350–1361 (2019).
Rackley, L. et al. RNA fibers as optimized nanoscaffolds for siRNA coordination and reduced immunological recognition. Adv. Funct. Mater. 28, 1805959 (2018).
Vessillier, S. et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials—whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J. Immunol. Methods 424, 43–52 (2015).
Gregg, K. A. et al. Rationally designed TLR4 ligands for vaccine adjuvant discovery. mBio 8, e00492-17 (2017).
Oh, D. Y. et al. Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures. Mol. Cell. Proteom. 15, 1877–1894 (2016).
Chandler, M., Johnson, B., Panigaj, M. & Afonin, K. A. Innate immune responses triggered by nucleic acids inspire the design of immunomodulatory nucleic acid nanoparticles (NANPs). Curr. Opin. Biotechnol. 63, 8–15 (2020).
Wei, M. et al. Polyvalent immunostimulatory nanoagents with self-assembled CpG oligonucleotide-conjugated gold nanoparticles. Angew. Chem. Int. Ed. Engl. 51, 1202–1206 (2012).
Radovic-Moreno, A. F. et al. Immunomodulatory spherical nucleic acids. Proc. Natl Acad. Sci. USA 112, 3892–3897 (2015).
Li, J. et al. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano 5, 8783–8789 (2011).
Liu, X. et al. A DNA nanostructure platform for directed assembly of synthetic vaccines. Nano Lett. 12, 4254–4259 (2012).
Wang, S. et al. Rational vaccinology with spherical nucleic acids. Proc. Natl Acad. Sci. USA 116, 10473–10481 (2019).
Hong, E. & Dobrovolskaia, M. A. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. Adv. Drug Deliv. Rev. 141, 3-22 (2018).
Dobrovolskaia, M. A. Nucleic acid nanoparticles at a crossroads of vaccines and immunotherapies. Molecules 24, 4620 (2019).
Kondo, S. & Sauder, D. N. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation. Eur. J. Immunol. 27, 1713–1718 (1997).
Phillips, A., Patel, C., Pillsbury, A., Brotherton, J. & Macartney, K. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 41, 329–346 (2018).
Miller, E. R. et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Hum. Vaccin. Immunother. 14, 1963-1969 (2018).
Woo, E. J., Moro, P. L., Cano, M. & Jankosky, C. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: reports to the Vaccine Adverse Event Reporting System. Vaccine 35, 5618–5621 (2017).
Gause, K. T. et al. Immunological principles guiding the rational design of particles for vaccine delivery. ACS Nano 11, 54–68 (2017).
Di Franco, S., Turdo, A., Todaro, M. & Stassi, G. Role of type I and II interferons in colorectal cancer and melanoma. Front. Immunol. 8, 878 (2017).
Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).
Chan, A. et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol. Ther. Nucleic Acids 4, e263 (2015).
Halman, J. R. et al. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (NANPS) for controlled gene silencing, immunostimulation, and biodistribution. Nanomedicine 23, 102094 (2020).
Bui, M. N. et al. Versatile RNA tetra-U helix linking motif as a toolkit for nucleic acid nanotechnology. Nanomedicine 13, 1137–1146 (2017).
Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355–29358 (2002).
Potter, T. M., Neun, B. W., Rodriguez, J. C., Ilinskaya, A. N. & Dobrovolskaia, M. A. Analysis of pro-inflammatory cytokine and type II interferon induction by nanoparticles. Methods Mol. Biol. 1682, 173–187 (2018).
Centers for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories 5th edn (US Department of Health and Human Services, 2009).
Strober, W. Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. 21, A.3B.1–A.3B.2 (2001).
Radvanyi, L. G., Banerjee, A., Weir, M. & Messner, H. Low levels of interferon-α induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand. J. Immunol. 50, 499–509 (1999).
Tam, M. A. & Wick, M. J. MyD88 and interferon-α/β are differentially required for dendritic cell maturation but dispensable for development of protective memory against Listeria. Immunology 128, 429–438 (2009).
Trepiakas, R., Pedersen, A. E., Met, O. & Svane, I. M. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 27, 2213–2219 (2009).
Floros, T. & Tarhini, A. A. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42, 539–548 (2015).
Cheknev, S. B., Kobyakina, N. A., Mezentseva, M. V. & Skvortsova, V. I. Long-term study of interferon system state in patients with multiple sclerosis received the individual immune therapy with human recombinant IFN-alpha. Russ. J. Immunol. 6, 39–46 (2001).
Bongioanni, M. R. et al. Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis. J. Neurol. Sci. 143, 91–99 (1996).
Kujawski, L. A. & Talpaz, M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 18, 459–471 (2007).
Rong, L. & Perelson, A. S. Modeling HIV persistence, the latent reservoir, and viral blips. J. Theor. Biol. 260, 308–331 (2009).
Stiff, A. & Carson, W. III Investigations of interferon-lambda for the treatment of cancer. J. Innate Immun. 7, 243–250 (2015).
Filipi, M. L. et al. Nurses’ perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. Int. J. MS Care 16, 55–60 (2014).
Rosenberg, A. S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112, 15–21 (2003).
Baker, M. P., Reynolds, H. M., Lumicisi, B. & Bryson, C. J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1, 314–322 (2010).
Chang, C. J. et al. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat. Commun. 8, 522 (2017).
Chen, B. M. et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal. Chem. 88, 10661–10666 (2016).
Chen, W. W., Zhang, X. & Huang, W. J. Role of neuroinflammation in neurodegenerative diseases (Review). Mol. Med. Rep. 13, 3391–3396 (2016).
Hsieh, Y. C. et al. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics 8, 3164–3175 (2018).
Cruz-Acuna, M., Halman, J. R., Afonin, K. A., Dobson, J. & Rinaldi, C. Magnetic nanoparticles loaded with functional RNA nanoparticles. Nanoscale 10, 17761–17770 (2018).
This study was supported in part by federal funds from the National Cancer Institute, National Institutes of Health, under contracts HHSN261200800001E and 75N91019D00024 (to M.A.D.). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Research reported in this publication was also supported by the National Institute of General Medical Sciences of the National Institutes of Health under award no. R01GM120487 (to K.A.A.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank J. Halman and M. Chandler of the University of North Carolina at Charlotte and E. Hong and E. Cedrone of the Nanotechnology Characterization Lab, National Cancer Institute, for excellent technical assistance.
The authors declare no competing interests.
Peer review information Nature Protocols thanks Remi Creusot, Chunhai Fan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Key references using this protocol
Hong, E. et al. Nano Lett. 18, 4309–4321 (2018): https://doi.org/10.1021/acs.nanolett.8b01283
Rackley, L. et al. Adv. Funct. Mater. 28, 1805959 (2018): https://doi.org/10.1002/adfm.201805959
Hong, E. et al. Molecules 24, 1094 (2019): https://doi.org/10.3390/molecules24061094
Afonin, K. A. et al. Nat. Protoc. 6, 2022–2034 (2011): https://doi.org/10.1038/nprot.2011.418
About this article
Cite this article
Dobrovolskaia, M.A., Afonin, K.A. Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles. Nat Protoc 15, 3678–3698 (2020). https://doi.org/10.1038/s41596-020-0393-6